PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32171145-0	2020	Low-dose naltrexone inhibits colorectal cancer progression and promotes apoptosis by increasing M1-type macrophages and activating the Bax/Bcl-2/caspase-3/PARP pathway.	Naltrexone	9-19	BCL2-associated X protein	Mus musculus	135-138	
25183508-13	2014	In the Naltrexone plus TM group, gene expression of Bax/Bcl-2 ratio and caspase3 significantly lowered compared with the TM group.	Naltrexone	7-17	BCL2-associated X protein	Mus musculus	52-55	
16716514-3	2006	The purpose of the present study was to analyse the effects of naltrexone on the expression levels of proteins regulating the extrinsic (FasL and Fas) and the mitochondrial (Bcl-2, Bcl-xL, Bad and Bax) apoptotic pathways, as well as the active fragment of the executioner caspase-3 in the mouse brain.	Naltrexone	63-73	BCL2-associated X protein	Mus musculus	197-200	
16716514-4	2006	Western blotting showed that a single injection of naltrexone (1 mg/kg) induced a down-regulation of the pro-apototic proteins Fas, FasL, Bad and Bax.	Naltrexone	51-61	BCL2-associated X protein	Mus musculus	146-149